Successful XXXX Rechallenge in Soft-Tissue @entity242 .

@entity1 @entity242 @entity1352 @entity1822 @entity3 @entity1260 @entity1821
OBJECTIVES: Treatment options for metastatic soft-tissue @entity242 are limited. The aim of this study was to investigate the clinical activity of @entity1260 rechallenge in @entity1352 ( @entity1352 ), @entity1821 ( @entity1821 ), @entity1822 ( @entity1822 ), and high-grade @entity242 not otherwise specified. METHODS: A retrospective search of the Royal Marsden @entity242 Unit Database was performed to identify @entity1 initially treated with @entity1260 (as single agent or in combination) and who were subsequently rechallenged with single-agent @entity1260 . Baseline demographics and response assessment were retrospectively obtained. RESULTS: Sixty-seven @entity1 were identified and the median age at diagnosis was 41 years (range, 18 to 71 y). There were 29 cases of @entity1352 , 17 of @entity1821 , 12 of @entity1822 , and 9 of @entity242 not otherwise specified. First-line @entity1260 -containing therapy was given to 14 @entity1 as adjuvant therapy (adjuvant group) and 53 @entity1 as palliative therapy (palliative group). Clinical activity (partial response or stable disease) with single-agent @entity1260 rechallenge was documented in 50.0% of @entity1 in the adjuvant group (7 in the second line) and 34.0% of @entity1 in the palliative group (15 in the second line, 1 in third line, and 2 in the fourth line). The median progression-free survival in @entity1 with documented clinical activity was 11.5 months (95% CI, 8.8-12.3) and 6.9 months (95% CI, 5.1-9.0), respectively, in the adjuvant and palliative group. @entity1260 rechallenge was mostly active in @entity1352 @entity1 (49.3%, 14 out of 29 @entity1 with partial remission or stable disease). CONCLUSIONS: @entity1260 rechallenge has clinical activity in soft-tissue @entity242 and can be considered a viable option in treating @entity3 .
